Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Endocrinology
Volume 2017 (2017), Article ID 7898713, 5 pages
https://doi.org/10.1155/2017/7898713
Case Report

Effect of Intranasal Calcitonin in a Patient with McCune-Albright Syndrome, Fibrous Dysplasia, and Refractory Bone Pain

1Gynecological Endocrinology Unit, Division of Endocrinology, Hospital de Clinicas de Porto Alegre, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil
2Laboratory of Molecular Endocrinology, Department of Physiology, Federal University of Rio Grande do Sul, Rua Ramiro Barcelos 2350, 90035-003 Porto Alegre, RS, Brazil

Correspondence should be addressed to Poli Mara Spritzer; rb.sgrfu@reztirps

Received 14 April 2017; Revised 12 May 2017; Accepted 18 May 2017; Published 6 June 2017

Academic Editor: Mihail A. Boyanov

Copyright © 2017 Tayane Muniz Fighera and Poli Mara Spritzer. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. E. Dumitrescu and M. T. Collins, “McCune-Albright syndrome,” Orphanet Journal of Rare Diseases, vol. 3, no. 1, article no. 12, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. E. S. Hart, M. H. Kelly, B. Brillante et al., “Onset, progression, and plateau of skeletal lesions in fibrous dysplasia and the relationship to functional outcome,” Journal of Bone and Mineral Research, vol. 22, no. 9, pp. 1468–1474, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. G. L. Plosker and D. McTavish, “A review of its pharmacological properties and role in the management of postmenopausal osteoporosis, Drugs aging,” Intranasal Salcatonin (Salmon Calcitonin), vol. 8, no. 5, pp. 378–400, 1996. View at Publisher · View at Google Scholar
  4. A. M. Boyce, A. Turner, L. Watts et al., “Improving patient outcomes in fibrous dysplasia/McCune-Albright syndrome: an international multidisciplinary workshop to inform an international partnership,” Archives of Osteoporosis, vol. 12, no. 1, 6 pages, 2017. View at Publisher · View at Google Scholar
  5. R. D. Chapurlat, “Medical therapy in adults with fibrous dysplasia of bone,” Journal of Bone and Mineral Research, vol. 21, no. 2, pp. 114–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. M. McCormack, D. J. Horne, and S. Sheather, “Clinical applications of visual analogue scales: a critical review,” Psychological Medicine, vol. 18, no. 4, pp. 1007–1019, 1988. View at Publisher · View at Google Scholar · View at Scopus
  7. M. D. Thomsen and L. Rejnmark, “Clinical and radiological observations in a case series of 26 patients with fibrous dysplasia,” Calcified Tissue International, vol. 94, no. 4, pp. 384–395, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Benhamou, D. Gensburger, C. Messiaen, and R. Chapurlat, “Prognostic Factors From an Epidemiologic Evaluation of Fibrous Dysplasia of Bone in a Modern Cohort: The FRANCEDYS Study,” Journal of Bone and Mineral Research, vol. 31, no. 12, pp. 2167–2172, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Boyce, M. H. Kelly, and B. A. Brillante, “A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 11, pp. 4133–4140, 2014. View at Publisher · View at Google Scholar
  10. N. H. Bell, S. Avery, and C. Conrad Johnston, “Effects of calcitonin in Pagets disease and polyostotic fibrous dysplasia,” J Clin Endocrinol, vol. 31, no. 3, pp. 283–290, 1970. View at Publisher · View at Google Scholar
  11. K. Yamamoto, I. Maeyama, H. Kishimoto et al., “Suppressive Effect of Elcatonin, an Eel Calcitonin Analogue, on Excessive Urinary Hydroxyproline Excretion in Polyostotic Fibrous Dysplasia (McCune-Albright's Syndrome),” Endocrinologia Japonica, vol. 30, no. 5, pp. 651–656, 1983. View at Publisher · View at Google Scholar · View at Scopus
  12. Å. Hjelmstedt and S. Ljunghall, “A case of albright's syndrome treated with calcitonin,” Acta Orthopaedica, vol. 50, no. 3, pp. 251–253, 1979. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Mystakidou, S. Befon, K. Hondros, E. Kouskouni, and L. Vlahos, “Continuous subcutaneous administration of high-dose salmon calcitonin in bone metastasis: Pain control and beta-endorphin plasma levels,” Journal of Pain and Symptom Management, vol. 18, no. 5, pp. 323–330, 1999. View at Publisher · View at Google Scholar · View at Scopus
  14. S. Tanaka, A. Yoshida, S. Kono, and M. Ito, “Effectiveness of monotherapy and combined therapy with calcitonin and minodronic acid hydrate, a bisphosphonate, for early treatment,” Journal of Orthopaedic Science, vol. 22, no. 3, pp. 536–541, 2017. View at Publisher · View at Google Scholar
  15. M. Esenyel, A. Içaǧasioǧlu, and C. Z. Esenyel, “Effects of calcitonin on knee osteoarthritis and quality of life,” Rheumatology International, vol. 33, no. 2, pp. 423–427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. G. P. Lyritis and G. Trovas, “Analgesic effects of calcitonin,” Bone, vol. 30, 5, pp. 71S–74S, 2002. View at Publisher · View at Google Scholar
  17. C. H. Chesnut III, M. Azria, S. Silverman, M. Engelhardt, M. Olson, and L. Mindeholm, “Salmon calcitonin: A review of current and future therapeutic indications,” Osteoporosis International, vol. 19, no. 4, pp. 479–491, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. R. Viana and M. W. C. Payne, “Use of calcitonin in recalcitrant phantom limb pain complicated by heterotopic ossification,” Pain Research and Management, vol. 20, no. 5, pp. 229–233, 2015. View at Publisher · View at Google Scholar · View at Scopus
  19. C. Gennari, “Analgesic effect of calcitonin in osteoporosis,” Bone, vol. 30, no. 5, pp. 67S–70S, 2002. View at Publisher · View at Google Scholar
  20. European Medicines Agency. European Medicines Agency recommends limiting long-term use of calcitonin medicines, Press release, 2012.
  21. P. M. Foye, P. Shupper, and I. Wendel, “Coccyx fractures treated with intranasal calcitonin,” Pain Physician, vol. 17, no. 2, pp. 233–229, 2014. View at Google Scholar · View at Scopus
  22. J. A. Knopp-Sihota, C. V. Newburn-Cook, J. Homik, G. G. Cummings, and D. Voaklander, “Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: A systematic review and meta-analysis,” Osteoporosis International, vol. 23, no. 1, pp. 17–38, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Liu, D. Q. Yang, F. Xie, B. Zhou, and M. Liu, “Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer,” Genetics and Molecular Research, vol. 13, no. 3, pp. 5285–5291, 2014. View at Publisher · View at Google Scholar · View at Scopus